Skip to main content
S&P 5007,659.44-1.09%DOW52,002.41-0.34%NASDAQ26,140.03-2.14%BTC$81,442.00-0.92%ETH$2,417.14-0.81%GOLD$4,186.70+0.40%OIL$99.04+2.63%
Smart Investors Daily
SID Premium
Gilead Sciences, Inc. logo

NYSE · GILD

Gilead Sciences, Inc.

Healthcare · Drug Manufacturers - General

$156.19

Down-$1.18 (-0.75%)

Updated Oct 19, 2026, 8:12 AM

SID Score

7.2/10

Composite research score

Smart Money

48/100

Neutral

Market cap
152.89B
P/E ratio
18.89
Dividend yield
2.52%
52-week range
$116.88 – $160.51
Volume
7.77M
Avg. volume
7.34M

Price performance · GILD

GILD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 16, 2026

GILD closed at $156.19 after 20 trading sessions, up 3.74% for the selected period.

Last close
$156.19
Period change
+3.74%
Period low
$144.23
Period high
$157.37
Daily close
View OHLC price history
GILD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 16, 2026$157.32$157.575$155.62$156.197.77M
Oct 15, 2026$156.39$160.51$156.02$157.378.29M
Oct 14, 2026$148.19$153.76$147.48$153.545.76M
Oct 13, 2026$151.16$151.16$147.26$147.926.23M
Oct 12, 2026$151.835$152.26$149.80$150.435.79M
Oct 9, 2026$147.23$151.44$146.10$151.175.8M
Oct 8, 2026$146.73$147.59$144.65$147.104.49M
Oct 7, 2026$145.275$148.60$144.85$146.855.1M
Oct 6, 2026$145.11$146.14$142.5982$144.233.72M
Oct 5, 2026$143.21$145.16$142.79$144.636.14M
Oct 2, 2026$147.65$148.00$144.00$144.745.04M
Oct 1, 2026$149.44$149.44$147.185$147.504.44M
Sep 30, 2026$150.875$151.28$148.98$149.055.36M
Sep 29, 2026$150.18$152.625$148.785$151.285.32M
Sep 28, 2026$149.795$152.74$149.41$152.215.08M
Sep 25, 2026$150.05$151.00$148.02$150.935.28M
Sep 24, 2026$151.10$152.975$149.59$149.695.08M
Sep 23, 2026$153.60$154.1999$150.06$151.376.19M
Sep 22, 2026$150.645$153.2807$148.65$152.675.08M
Sep 21, 2026$150.11$152.095$148.22$150.565.57M

Latest GILD news

The latest Smart Investors Daily articles mentioning GILD.

Stock researchCompany · Overview

GILD research

Overview

Company profile and research snapshot.

Company profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$130.64
Implied upside
—
Analysts
16
GILD recent ratings
DateFirmRatingTarget
Oct 8, 2026RBC CapitalSector Perform—
Oct 8, 2026Cantor FitzgeraldOverweight—
Oct 7, 2026JP MorganOverweight—
Oct 7, 2026Truist SecuritiesBuy—
Oct 7, 2026Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 17, 2026

Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News?

Vir Biotechnology has seen sharp swings over the past few years, which puts fresh focus on a simple question for anyone looking at the stock today: Does the current share price line up with what the business is generating from its sales? Over the last 5 years, the share price has fallen 75.2%, which puts a lot of weight on whether the current valuation still fits the company’s revenue base. The new collaboration with Gilead on dual masked T cell engagers, along with fast track status for...

Yahoo · Oct 15, 2026

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

FOSTER CITY, Calif., October 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By